Opus Genetics, Inc.

Stocks

IRD

US67577R1023

Market Closed - Nasdaq 16:00:00 2026-08-18 EDT			5-day change	1st Jan Change
3.690 ^USD	+1.10%		-4.90%	+83.58%

08-07	RBC Adjusts PT on Opus Genetics to $9 From $10, Maintains Outperform Speculative Risk Rating	MT
08-06	Opus Genetics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI

Transcript : Opus Genetics, Inc. - Special Call

Published on 06/16/2026 at 04:50 pm EDT - Modified on 06/25/2026 at 02:51 pm EDT

S&P Capital IQ

Presenter Speech
Benjamin Yerxa (Executives)

Good morning, and thank you for joining us today to delve into our gene therapy pipeline with a focus on our earlier-stage programs. As a reminder, this

This article is reserved for our subscribers.

To unlock the article,
subscribe!

Full unlimited browsing across the entire site

Access to all the news and all the data

Access to US, EUROPE AND ASIA Portfolios

Zero Ads for a completely uninterrupted reading experience

Pro Tools: Expert insights, Expert Screeners, historical financial data and reports, thematic lists, transcripts...

Latest news about Opus Genetics, Inc.

08-07	RBC Adjusts PT on Opus Genetics to $9 From $10, Maintains Outperform Speculative Risk Rating	MT
08-06	Opus Genetics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-03	Opus Genetics Completes Enrollment in Phase 3 Gene Therapy Trial for Rare Blindness Disorder	MT
08-03	Opus Genetics Completes Enrollment in Registrational Phase 3 Trial of OPGx-LCA5 For LCA5-Associated Inherited Retinal Disease	CI
07-29	TD Cowen Initiates Opus Genetics at Buy	MT
07-09	Opus Genetics Provides Update On OPGx-BEST1 Program With Detailed Timeline For OPGx-BEST1 Results	CI
07-06	Opus Genetics Unlocks Key Milestone With US FDA Alignment on OPGx-LCA5 Phase 3, Wedbush Says	MT
07-06	Opus Genetics Announces FDA Alignment on Phase 3 Registrational Trial Design for Opgx-Lca5 in Lca5-Associated Inherited Retinal Disease	CI
07-06	Opus Genetics Reaches Alignment With US FDA on Phase 3 Trial of OPGx-LCA5 to Treat Retinal Disease	MT
06-29	Opus Genetics, Inc.(NasdaqCM:IRD) added to Russell Small Cap Comp Growth Benchmark	CI
06-29	Opus Genetics, Inc.(NasdaqCM:IRD) added to Russell 2500 Growth Benchmark	CI
06-29	Opus Genetics, Inc.(NasdaqCM:IRD) added to Russell 2000 Index	CI
06-29	Opus Genetics, Inc.(NasdaqCM:IRD) added to Russell Microcap Growth Benchmark Index	CI
06-29	Opus Genetics, Inc.(NasdaqCM:IRD) added to Russell 2000 Growth Benchmark	CI
06-29	Opus Genetics, Inc.(NasdaqCM:IRD) added to Russell 3000E Growth Benchmark	CI